Today: 21 May 2026
Browse Category

NYSE:PFE 21 January 2026 - 5 February 2026

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 February 2026
·
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
··
Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 February 2026
··
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer shares fell 3.4% to $25.76 early Tuesday after quarterly results and new Phase 2b obesity drug data. The company reported adjusted Q4 earnings of 66 cents per share on $17.56 billion revenue, both above analyst estimates. Pfizer reaffirmed its 2026 outlook and does not plan share buybacks this year. COVID-19 product sales continued to decline sharply.
3 February 2026
··
Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer shares rose 0.3% to $26.51 ahead of fourth-quarter and full-year 2025 results due Feb. 3. Analysts expect adjusted earnings of 57–58 cents per share on $16.7–16.9 billion revenue. Obesity drug price cuts and a UK ruling against Sanofi in an RSV dispute add pressure. Pfizer projects 2026 revenue of $59.5–62.5 billion, factoring in losses from COVID-19 products and patent expirations.
2 February 2026
·
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer shares rose 0.7% to $25.84 in Monday afternoon trading, tracking a broader U.S. stock rally ahead of major earnings and a Federal Reserve policy decision. Investors are watching for Pfizer’s Feb. 3 earnings and updates on its 2026 outlook, as the company faces falling COVID demand and looming patent expirations. Trading volume remained moderate, with no major company news released.
26 January 2026
····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
1 2 3 4 … 10

Stock Market Today

  • easyJet Shares Drop 64% Over Five Years: Is It Time to Buy?
    May 21, 2026, 6:21 AM EDT. easyJet posted a larger loss before tax of £552 million for the six months ending March 31, worsening from last year's £394 million loss amid rising fuel prices and global conflicts. CEO Kenton Jarvis emphasizes the airline's strong liquidity position with £434 million net cash and total liquidity of £4.7 billion, helping it endure short-term challenges. Despite market volatility, easyJet's valuation appears attractive with forecasts suggesting a price-to-earnings ratio falling below five by 2028. Analysts caution risks from ongoing geopolitical disruptions. Investors must weigh easyJet's robust balance sheet and long-term potential against persistent uncertainties in the aviation sector.

Latest articles

Dow slides 406 points as the AI surge stalls and an oil shock rattles the US market

US Futures Edge Up After Nvidia Earnings, Wall Street Watches AI Stocks

21 May 2026
U.S. stock index futures rose slightly early Thursday, with Dow futures up 111 points and S&P 500 and Nasdaq 100 futures posting smaller gains. Nvidia reported record quarterly revenue of $81.6 billion and announced an $80 billion share buyback, but shares slipped in premarket trading. The U.S. 10-year Treasury yield hovered near 4.58%. Oil prices edged lower amid ongoing Middle East developments.
Nu Holdings Shares Rebound as Street Scrutinizes Credit Again

Nu Holdings Shares Rebound as Street Scrutinizes Credit Again

21 May 2026
Nu Holdings shares hovered near $12.79 in early New York indications Thursday after a 4.1% rebound, but remained down 23.6% for 2026. UBS cut its price target to $16.90 from $18.10 while keeping a Buy rating. The company reported record first-quarter revenue and profit but increased loan-loss reserves, raising investor concerns over credit quality.
Nokia Shares Slide as Company Moves on AI Networking

Nokia Shares Slide as Company Moves on AI Networking

21 May 2026
Nokia shares fell 0.7% to 11.650 euros in Helsinki on Thursday, underperforming the OMX Helsinki 25 index, after the company opened a new AI Networking Innovation Lab in Sunnyvale, California. The stock had recently hit a 16-year high following strong first-quarter results and a surge in AI and cloud orders.
Go toTop